

#### **Contact**

T +49 (0)89 747 266 0 F +49 (0)89 776 424





Dr. Matthias Hoffmann
Associate
German Patent Attorney
M.Sc. Pharmaceutical Sciences

Matthias is a patent attorney at Maiwald. His work covers all aspects of patent prosecution in the fields of pharmaceuticals and chemistry. In the course of his doctoral research, Matthias investigated new active ingredients for the treatment of Alzheimer´s disease, radioactive molecules for use in medical research as well as flavors and odors in the area of food chemistry. His research results have been published in prestigious medicinal chemistry journals. He is co-inventor of two PCT patents.

#### **CAREER**

since 2023	German patent attorney at Maiwald
2020 - 2023	Patent attorney trainee at Maiwald
2019 - 2020	Postdoc researcher at the institute Mécanismes Maoléculaires dans les Démences Neurodégénératives (MMDN, INSERM) of the University of Montpellier
2016 - 2019	Research assistant at the Chair of Pharmaceutical and Medicinal Chemistry of the Julius Maximilian University of Würzburg

### **EDUCATION**

2023	Admitted to practice as German patent attorney
2020 - 2023	Studied law for patent attorneys at the University of Hagen
2016 - 2019	Doctoral degree in the field of of medicinal and organic chemistry at the Julius- Maximilians-University Würzburg
2013 - 2015	Master's degree in pharmaceutical sciences at the Westphalian Wilhelms University of Münster
2010 - 2013	Bachelor's degree in chemistry at the University of Paderborn

### **PRACTICE AREAS**

- Pharma & Biotech
- Organic Chemistry & Polymers
- Patents & Utility Models

### **SERVICES**

Patent prosecution and portfolio management

- Filing strategies and drafting patent applications
- Freedom-to-operate- and validity opinions
- Opposition proceedings

# **RECOGNITIONS**

- Best poster award at the "Frontiers in Medicinal Chemistry" conference of the Gesellschaft Deutscher Chemiker 2019
- PhD scholarship of the "Studienstiftung des Deutschen Volkes"

## **PUBLICATIONS**

• Clarification on the transfer of priority rights expected at the EPO

## **LANGUAGES**

- German
- English
- French